nPhase Mixes Data, Evidence in One Platform, N-Power Medicine, VieCure Enter Partnership, More

nPhase Mixes Data, Evidence in One Platform, N-Power Medicine, VieCure Enter Partnership, More

By Clinical Research Staff

September 25, 2025 | nPhase launches the first industry platform to harmonize real-world evidence and clinical trial data in one system; N-Power Medicine and VieCure have entered a strategic partnership; and more.

nPhase has launched REDCap Cloud 2.0, the first industry platform to harmonize real-world evidence and clinical trial data in one system. With an interoperable architecture, the platform addresses the complex data needs of global-scale research while laying the foundation for AI adoption that will transform the future of research innovation and how life sciences organizations design, run, and analyze studies. Press release.

N-Power Medicine and VieCure announced a strategic partnership to bring N-Power Medicine’s proprietary Kaleido Registry to the VieCure network. Through this collaboration, VieCure’s community oncology practices will gain access to both VieCure’s Halo Intelligence Platform and N-Power’s next-generation infrastructure, including its always-on Prospective External Control Arm (ProECA) platform. The collaboration addresses a critical gap in cancer drug development, where fewer than 5% of adult cancer patients participate in clinical trials, often due to limited access in community settings where 85% of patients receive care. Press release.

Elsevier launched PharmaPendium AI, a generative AI assistant for regulatory intelligence in drug development. PharmaPendium AI, layered on top of PharmaPendium, the company’s regulatory tool, delivers citation-backed answers to complex regulatory questions in seconds, helping users move faster with greater confidence. It streamlines the discovery and contextualization of actionable insights using retrieval augmented generation (RAG) and natural language processing. The solution is designed to transform how regulatory affairs professionals, preclinical, and clinical researchers access and apply information from US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory documents. Press release.

Veeva Systems announced a collaboration with Amgen to advance clinical trial innovation. Amgen will employ the Veeva Clinical Platform to support and identify efficiencies across the clinical trial process. As part of the collaboration, Veeva Business Consulting will support Amgen through implementation and change management. Press release.

Pluto Health announced the launch of Connect, Assess, Review and Engage (C.A.R.E) on Deck, a care hub that guides patients to personalized health options, designed to empower patients to take an active role in their health. The platform uncovers meaningful opportunities for people—such as getting labs done at home and asynchronous or real-time clinician chats—while seamlessly integrating access to clinical research as a care option. Press release.

Veracyte has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test. The milestone marks an important step in Veracyte’s goal of making the novel molecular test widely available and helping clinicians to better guide next steps for patients with potentially cancerous lung nodules. The Percepta Nasal Swab test uses a simple brush to acquire nasal epithelial cells for the assessment of molecular changes linked to lung cancer risk in patients with lung nodules and a history of smoking. The prospective, randomized, blinded NIGHTINGALE trial has now successfully enrolled 2,400 patients at over 90 academic and community centers across the US. Press release.